ACHF.F Share Price Performance
US$0.41
-1.37 (-77.24%)
Price US$0.41
Share Pricen/a
Arch Biopartners Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ACHF.F Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Arch Biopartners Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.04
- -284.90%
- -1,705.36%
- -73.2%
About ACHF.F
- Founded
- n/a
- Employees
- n/a
- CEO
- WebsiteView website
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.
